Increasing Vascular Complications Depends on The Duration Disease of Having Been Diabetic Type 2

Authors

  • Zahraa Majid Ismail Chemistry Department, College of Science, Mustansiriyah University.
  • Zyad Hussein Jawad Chemistry Department, College of Science, Mustansiriyah University.
  • Ali Jasim Hammood Pharmacy Department, Al-Kut University College.

DOI:

https://doi.org/10.23851/mjs.v31i3.848

Keywords:

Endothelin (ET-1), diabetes type II (T2-DM), Insulin resistance (IR), Lipid profile.

Abstract

Angiopathy is a major complication in (T2-DM), Endothelin-1 (ET-1) is considered the main vasoconstrictor (a mitogenic endothelium-derived peptide is mostly, produced by endothelial cells, as well by vascular smooth muscle cells, macrophages, and other cells). Previous studies suggested a link between T2-DM and ET-1. This paper aims to study the association between Endothelin-1 (ET-1) as a marker of endothelial dysfunction and the duration disease among patients with T2-DM, and to identify the effects of obesity and insulin resistance on elevated Endothelin level. The study includes 96 patients with T2-DM, aged between (45-70) years, (56.73 ± 9.14 years) is an average duration of having T2-DM (14.541± 11.462) years, and 96 healthy control subjects, aged (45-70) years, (56.42 ± 8.74 years). We show that the excess of ET-1 level was clearly linked with the duration of T2-DM, where the plasma Endothelin level was significantly changed among the studied groups (according to their duration) (11.607 ±0.783), (13.641± 0.729), (17.736 ± 3.409), (33.816 ± 12.902), (81.165 ± 35.404), and (156.783 ± 12.671) pg/mL respectively. Plasma ET-1 levels significant is positively correlated with T2-DM (R² = 0.9711, p ≤ 0.01), with obesity, insulin resistance, age, HOMO-IR, hypertension, and HDL level (p ≤ 0.05). As a conclusion, the plasma ET-1 level was significantly elevated as long as having been T2-DM.

References

Cecil, R.L.F., Goldman, L. and Schafer, A.I., 2012. Goldman's Cecil Medicine, Expert Consult Premium Edition--Enhanced Online Features and Print, Single Volume, 24: Goldman's Cecil Medicine (Vol. 1). Elsevier Health Sciences.

Akushevich, I., Yashkin, A.P., Kravchenko, J., Fang, F., Arbeev, K., Sloan, F. and Yashin, A.I., 2018. Identifying the causes of the changes in the prevalence patterns of diabetes in older US adults: A new trend partitioning approach. Journal of Diabetes and its Complications, 32(4), pp.362-367. DOI: https://doi.org/10.1016/j.jdiacomp.2017.12.014

CrossRef | PubMed

Laakso, M. and Kuusisto, J., 2014. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nature Reviews Endocrinology, 10(5), p.293. DOI: https://doi.org/10.1038/nrendo.2014.29

CrossRef | PubMed

Tanfin, Z., Robin, P., Oyeniran, C. and Breuiller-Fouché, M., 2011. Endothelin-1: physiological and pathological roles in myometrium. The international journal of biochemistry & cell biology, 43(3), pp.299-302. DOI: https://doi.org/10.1016/j.biocel.2010.10.009

CrossRef | PubMed

De Nucci, G., Thomas, R., D'Orleans-Juste, P., Antunes, E., Walder, C., Warner, T.D. and Vane, J.R., 1988. Pressor effects of circulating Endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proceedings of the National Academy of Sciences, 85(24), pp.9797-9800. DOI: https://doi.org/10.1073/pnas.85.24.9797

CrossRef | PubMed

Chatterjee, S., Khunti, K., Davies, M.J., 2017. Type 2 diabetes. Lancet 389: 2239e2251.

CrossRef DOI: https://doi.org/10.1016/S0140-6736(17)30058-2

Clayton, D., Woo, V. and Yale, J.F., 2013. Hypoglycemia. Canadian journal of diabetes, 37, pp.S69-S71. DOI: https://doi.org/10.1016/j.jcjd.2013.01.022

CrossRef | PubMed

Wagner, O.F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P.J., Schneider, B., Waldh?usl, W. and Binder, B.R., 1992. Polar secretion of Endothelin-1 by cultured endothelial cells. Journal of Biological Chemistry, 267(23), pp.16066-16068. DOI: https://doi.org/10.1016/S0021-9258(18)41966-7

Fagan, T.C. and Deedwania, P.C., 1998. The cardiovascular dysmetabolic syndrome. The American journal of medicine, 105(1), pp.77S-82S.

CrossRef DOI: https://doi.org/10.1016/S0002-9343(98)00216-2

Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T., 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. nature, 332(6163), p.411. DOI: https://doi.org/10.1038/332411a0

CrossRef | PubMed

Barham, D. and Trinder, P., 1972. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst, 97(1151), pp.142-145. DOI: https://doi.org/10.1039/an9729700142

CrossRef | PubMed

Flier, J.S., Kahn, C.R. and Roth, J., 1979. Receptors, antireceptor antibodies and mechanisms of insulin resistance. New England Journal of Medicine, 300(8), pp.413-419. DOI: https://doi.org/10.1056/NEJM197902223000808

CrossRef | PubMed

Association between Radiation Exposure and Endothelium-Dependent Vasodilation: Results from Clinical and Experimental Studies Zhu Z, et al, Journal of Vascular and Interventional Radiology, 2019.

Fossati, P. and Prencipe, L., 1982. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clinical chemistry, 28(10), pp.2077-2080. DOI: https://doi.org/10.1093/clinchem/28.10.2077

CrossRef | PubMed

Allain, C.C., Poon, L.S., Chan, C.S., Richmond, W.F.P.C. and Fu, P.C., 1974. Enzymatic determination of total serum cholesterol. Clinical chemistry, 20(4), pp.470-475. DOI: https://doi.org/10.1093/clinchem/20.4.470

CrossRef | PubMed

Penttil?, I.M., Voutilainen, E., Laitinen, P. and Juutilainen, P., 1981. Comparison of different analytical and precipitation methods for direct estimation of serum high-density lipoprotein cholesterol. Scandinavian journal of clinical and laboratory investigation, 41(4), pp.353-360. DOI: https://doi.org/10.3109/00365518109092057

CrossRef | PubMed

Devasagayam, T.P., Tarachand, U., 1987. Decreased lipid peroxidation in the rat kidney during gestation. Biochem. Biophys. Res. Commun. 145, 134-138.

CrossRef DOI: https://doi.org/10.1016/0006-291X(87)91297-6

Ali, H., Rustam, R., Aprilia, D., Arizal, C., Gusadri, I.B. and Utami, P.R., 2019. Upregulation of SCUBE2 expression in dyslipidemic type 2 diabetes mellitus is associated with Endothelin-1. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(5), pp.2869-2872. DOI: https://doi.org/10.1016/j.dsx.2019.07.058

CrossRef | PubMed

Haak, T., Jungmann, E., Felber, A., Hillmann, U. and Usadel, K.H., 1992. Increased Plasma Levels of Endothelin in Diabetic Patients With Hypertension: An Alternative Viewpoint. American journal of hypertension, 5(3), pp.161-166. DOI: https://doi.org/10.1093/ajh/5.3.161

CrossRef | PubMed

Gursel Aka, Suleyman Buyukberbera, Alper Sevinca , H., Mehmet Turka , Mehmet Atesa, Ramazan Saria, Haluk Savlia, Ahmet Ciglib., 2001. The relation between plasma Endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. Diabetes and Its Complications 15, 150 - 157.

CrossRef DOI: https://doi.org/10.1016/S1056-8727(01)00137-4

Schneider, J.G., Tilly, N., Hierl, T., Sommer, U., Hamann, A., Dugi, K., Leidig-Bruckner, G. and Kasperk, C., 2002. Elevated plasma Endothelin-1 levels in diabetes mellitus. American journal of hypertension, 15(11), pp.967-972.

CrossRef DOI: https://doi.org/10.1016/S0895-7061(02)03060-1

Güvener, N., Aytemir, K., Aks?yek, S. and Gedik, O., 1997. Plasma Endothelin-1 levels in non-insulin dependent diabetes mellitus patients with macrovascular disease. Coronary artery disease, 8(5), pp.253-258. DOI: https://doi.org/10.1097/00019501-199705000-00001

CrossRef | PubMed

Bertello, P., Veglio, F., Pinna, G., Gurioli, L., Molino, P., Alban, S. and Chiandussi, L., 1994. Plasma Endothelin in NIDDM patients with and without complications. Diabetes Care, 17(6), pp.574-577.

CrossRef | PubMed

Veglio, F., Bertello, P., Pinna, G., Mulatero, P., Rossi, A., Gurioli, L., Panarelli, M. and Chiandussi, L., 1993. Plasma Endothelin in essential hypertension and diabetes mellitus. Journal of human hypertension, 7(4), pp.321-325.

Bertello, P., Veglio, F., Pinna, G., Gurioli, L., Molino, P., Alban, S. and Chiandussi, L., 1994. Plasma Endothelin in NIDDM patients with and without complications. Diabetes Care, 17(6), pp.574-577. DOI: https://doi.org/10.2337/diacare.17.6.574

CrossRef | PubMed

Takahashi, K., Ghatei, M.A., Lam, H.C., O'halloran, D.J. and Bloom, S.R., 1990. Elevated plasma Endothelin in patients with diabetes mellitus. Diabetologia, 33(5), pp.306-310. DOI: https://doi.org/10.1007/BF00403325

CrossRef | PubMed

Ahlborg, G., Shemyakin, A., B?hm, F., Gonon, A. and Pernow, J., 2007. Dual Endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care, 30(3), pp.591-596. DOI: https://doi.org/10.2337/dc06-1978

CrossRef | PubMed

Gaboury, C.L., Simonson, D.C., Seely, E.W., Hollenberg, N.K. and Williams, G.H., 1994. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. The Journal of clinical investigation, 94(6), pp.2295-2300. DOI: https://doi.org/10.1172/JCI117593

CrossRef | PubMed

Ishibashi, K.I., Imamura, T., Sharma, P.M., Huang, J., Ugi, S. and Olefsky, J.M., 2001. Chronic Endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. The Journal of clinical investigation, 107(9), pp.1193-1202. DOI: https://doi.org/10.1172/JCI11753

CrossRef | PubMed

Shaw, S.G. and Boden, P.J., 2005. Insulin resistance, obesity and the metabolic syndrome. Is there a therapeutic role for Endothelin-1 antagonists?. Current vascular pharmacology, 3(4), pp.359-363. DOI: https://doi.org/10.2174/157016105774329471

CrossRef | PubMed

Wheatcroft, S.B., Williams, I.L., Shah, A.M. and Kearney, M.T., 2003. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabetic Medicine, 20(4), pp.255-268. DOI: https://doi.org/10.1046/j.1464-5491.2003.00869.x

CrossRef | PubMed

Seligman, B.G., Biolo, A.N.D.R.E.I.A., Polanczyk, C.A., Gross, J.L. and Clausell, N., 2000. Increased plasma levels of Endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 23(9), pp.1395-1400. DOI: https://doi.org/10.2337/diacare.23.9.1395

CrossRef | PubMed

Cuchel, M. and Rader, D.J., 2006. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation, 113(21), pp.2548-2555. DOI: https://doi.org/10.1161/CIRCULATIONAHA.104.475715

CrossRef | PubMed

Njajou, O.T., Kanaya, A.M., Holvoet, P., Connelly, S., Strotmeyer, E.S., Harris, T.B., Cummings, S.R. and Hsueh, W.C., 2009. Association between oxidized LDL, obesity and type 2 diabetes in a population?based cohort, the Health, Aging and Body Composition Study. Diabetes/metabolism research and reviews, 25(8), pp.733-739. DOI: https://doi.org/10.1002/dmrr.1011

CrossRef | PubMed

Steinberg, D., 1997. Low density lipoprotein oxidation and its pathobiological significance. Journal of Biological Chemistry, 272(34), pp.20963-20966. DOI: https://doi.org/10.1074/jbc.272.34.20963

CrossRef | PubMed

Boulanger, C.M., Tanner, F.C., Bea, M.L., Hahn, A.W., Werner, A. and Lüscher, T.F., 1992. Oxidized low density lipoproteins induce mRNA expression and release of Endothelin from human and porcine endothelium. Circulation Research, 70(6), pp.1191-1197. DOI: https://doi.org/10.1161/01.RES.70.6.1191

CrossRef | PubMed

Downloads

Published

2020-08-20

How to Cite

[1]
Z. M. Ismail, Z. H. Jawad, and A. J. Hammood, “Increasing Vascular Complications Depends on The Duration Disease of Having Been Diabetic Type 2”, MJS, vol. 31, no. 3, pp. 28–34, Aug. 2020.

Issue

Section

Chemical Science

Most read articles by the same author(s)